Anti-platelet therapy: glycoprotein IIb-IIIa antagonists
نویسندگان
چکیده
منابع مشابه
Glycoprotein IIb/IIIa antagonists
The role of GP IIb/IIIa antagonists has been focused on patients with acute coronary syndromes undergoing PCI. In the ISAR-REACT 2 study abciximab given in patients with NSTEACS undergoing PCI already treated with 600 mg clopidogrel improved 30-day death and reinfarction rate in troponin positive patients. In the large EARLY-ACS trial upstream therapy with eptifibatide in high risk with NSTE-AC...
متن کاملPlatelet glycoprotein IIb/IIIa antagonists: pharmacology and clinical developments.
PLATELETS are critical for normal hemostasis and thrombus formation. Thrombus formation initiated by platelets plays a central role in the pathogenesis of acute coronary syndromes (unstable angina and myocardial infarction). Platelets are involved in events causing angioplasty failure and stent thrombosis and may also play an important role in restenosis through the release of potent prothrombo...
متن کاملPlatelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
CONTEXT Thrombus formation on disrupted atherosclerotic plaque is the major cause of acute coronary events. Platelet inhibitors are the mainstay of drug therapy to reduce cardiac events in patients with acute coronary syndromes. The platelet glycoprotein (GP) IIb/IIIa receptor is the final common pathway of platelet aggregation. OBJECTIVES To review mechanisms of platelet activation and aggre...
متن کاملPlatelet Glycoprotein IIb/IIIa Inhibitors
Glycoprotein IIb/IIIa (GPIIb-IIIa) complexes (integrin aIIbb3) mediate platelet aggregation by binding fibrinogen or von Willebrand factor (vWF), protein cofactors that form bridges between adjacent platelets. The cross-linked adhesive proteins assemble platelets into the aggregate. Agents that block the function of the GPIIb-IIIa complex of platelets constitute a powerful new generation of ant...
متن کاملPlatelet glycoprotein IIb/IIIa inhibitors.
To the Editor: Platelet glycoprotein (GP) IIb/IIIa antagonists only prompt an overall 8.5% relative reduction in 30-day deaths or myocardial infarction in acute coronary syndromes (ACS),1 and Quinn et al1 suggested that this limited benefit may be due to factors such as antagonist-induced platelet activation. I suggest that limited benefits of GP IIb/IIIa inhibition are due basically to limited...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Clinical Pharmacology
سال: 2011
ISSN: 0306-5251
DOI: 10.1111/j.1365-2125.2010.03879.x